Case Report

Nonalpine Thyroid Angiosarcoma in a Patient with Hashimoto Thyroiditis

Nadia Innaro, Elena Succurro, Giuseppe Tomaino, and Franco Arturi

1 Department of Surgery, Policlinico “Mater Domini” of Catanzaro, Campus Universitario, Viale Europa, 88100 Catanzaro, Italy
2 Department of Medical and Surgical Sciences, University “Magna Graecia” of Catanzaro Policlinico “Mater Domini”, Campus Universitario, Viale Europa, 88100 Catanzaro, Italy

Correspondence should be addressed to Franco Arturi; arturi.franco@libero.it

Received 11 September 2013; Accepted 9 October 2013

Academic Editors: F. Micci and O. Ozyilkan

Copyright © 2013 Nadia Innaro et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Thyroid angiosarcoma is an uncommon thyroid carcinoma and its incidence is the highest in the European Alpine regions. Thyroid angiosarcoma is also a very aggressive tumor that can rapidly spread to the cervical lymph nodes, lungs, and brain or can metastasize to the duodenum, small bowel, and large bowel and induces severe bleeding [1–4]. Although it is histologically defined as cleft-like anastomosing spaces lined by large, atypical cells of endothelial lineage [7], clear-cut separation between the angiosarcoma and anaplastic thyroid carcinoma is difficult because they yield nearly the same clinical prognosis and overlapping histologic findings. Indeed, the existence of thyroid angiosarcoma has been a matter of debate for many years because some authors believe that most if not all angiosarcoma are in fact “angiomatoid” anaplastic carcinomas [8–11].

Angiosarcoma treatment is complex and consisting of surgery, chemotherapy, and radiotherapy.

We report the first case of thyroid angiosarcoma identified in Southern Italy (Calabria), in nonalpine area.

1. Introduction

Thyroid angiosarcoma is a very rare disease. As previously reported by other authors, its incidence is the highest in the European Alpine regions and in some European areas as Northern Italy, Austria, and Switzerland it can constitute the 2–10% of malignant thyroid tumors [1–3]. In Southern Italy, no case of thyroid angiosarcoma has been described. Thyroid angiosarcoma is also a very aggressive tumor that can rapidly spread to the cervical lymph nodes, lungs, and brain or can metastasize to the duodenum, small bowel, and large bowel and induce severe bleeding [1, 4–6]. Although it is histologically defined as cleft-like anastomosing spaces lined by large, atypical cells of endothelial lineage [7], clear-cut separation between the angiosarcoma and anaplastic thyroid carcinoma is difficult because they yield nearly the same clinical prognosis and overlapping histologic findings. Indeed, the existence of thyroid angiosarcoma has been a matter of debate for many years because some authors believe that most if not all angiosarcoma are in fact “angiomatoid” anaplastic carcinomas [8–11].

Angiosarcoma treatment is complex and consisting of surgery, chemotherapy, and radiotherapy.

We report the first case of thyroid angiosarcoma identified in Southern Italy (Calabria), in nonalpine area.

2. Case Report

On November 2011, a 49-year-old Caucasian female patient, born and resident in Southern Italy (Calabria), in an iodine-sufficient area, was admitted to the Surgery Department because she presented with a painless mass in the anterior region of neck enlarged rapidly in the last three months. After total thyroidectomy and right cervical lymphadenectomy, postoperative histological examination revealed the presence of a thyroid angiosarcoma with positive staining for CD31 and for both Factor VIII-related antigen and Vimentin and only partially positive for staining pancytokeratin and presence of metastasis in cervical, supraclavicular, mediastinal and paratracheal lymph nodes. The patient started adjuvant chemotherapy and she was treated for 6 cycles with Doxorubicin, Dacarbazine, Ifosfamide, and Mesna (MAID). After 22 months from surgery, the patient is still alive without both local and systemic recurrence of the disease.
enlargement of the right lobe in which a nodular lesion was present. In contrast, the left lobe of the thyroid gland was nonpalpable. There was evidence of involvement of cervical lymph nodes.

Thyroid gland high-resolution ultrasonography confirmed the enlargement only of the right lobe that showed a morphology suggestive of an autoimmune thyroid disease and the presence of nodular lesion measuring 7.5 × 5.5 × 6 cm. In contrast, the left lobe was of normal size and normal structure. I131-scintiscanning showed that the nodule in the right lobe was hypofunctioning. The thyroid function was evaluated by measuring serum levels of free T3 (FT3), free T4 (FT4), and thyrotropin (TSH). Free T3 and free T4 levels were measured by RIA (Radim Spa, Roma, Italy). Plasma TSH levels were measured by IRMA (TSH Bridge, Biocem ImmunoSystems Italia, SpA, Milano, Italy). The results of thyroid function tests were within the normal range. The assay of the thyroid antibodies revealed a normal value of antithyroglobulin antibody and a positivity of the antithyroperoxidase antibody (8624 U/mL; normal value = 1–100).

The patient showed also iron deficiency anemia. Indeed, the blood values were the following: red blood cell count (RBC) is 4.17 × 10^6/uL (normal value is 4.2–5.4 × 10^6/uL), hemoglobin (Hb) is 8.8 gr/dL (normal value is 12–14 gr/dL), hematocrit 30.2 (normal value is 37–47%), mean corpuscular volume (MCV) is 72.4 fL (normal value is 81–99 fL), and mean corpuscular hemoglobin (MCH) is 26 pg (normal value is 27–31 PG), mean corpuscular hemoglobin concentration (MCHC) is 30 g/dL (normal value is 33–37 g/dL). Iron is 26 μg/dL (normal value is 37–145 μg/dL). White blood cell and platelet counts were within normal limits.

Neck computerized tomography confirmed the presence of a large vascular mass that measured 7.5 × 6 × 6 cm arising from the right thyroid lobe, which was described as necrotic and containing areas of calcification. There was significant mass effect with displacement of trachea to the left and there was compression of carotid bundle to the right. There was also involvement of both cervical and supraclavicular lymph nodes. There was no invasion of adjacent structures. Chest X-ray films showed clear lung fields.

After iron supplementation and normalization of the hemoglobin value, the patient underwent total thyroidectomy and right cervical lymphadenectomy.

Histological examination showed a well-circumscribed nodule confined within the thyroid and with large areas of necrotic fibrinous tissue. Microscopic examination disclosed a proliferation of epithelioid cells with enlarged pleomorphic nuclei and prominent nucleoli (Figure 1(a)). In several point of the tumor was possible to demonstrate the presence of irregular vascular areas containing hematic material bordered by atypical cells with intraluminal papillary projections (Figure 1(b)). The thyroid tissue unaffected by the tumor disclosed Hashimoto thyroiditis. Furthermore, in two cervical lymph nodes excised, the presence of metastatic tissue has been demonstrated.

On immunohistochemical examination, tumor cells showed both extensive and intensive immunoreactivity for CD31 (Figure 2(a)); they were positive for Factor VIII-related antigen (Figure 2(b)) and Vimentin and only partially positive for pancytokeratin (Figure 2(c)). Tumor cells were negative for thyroglobulin, TTF-1, CD34, cytokeratin 7, cytokeratin 20, and cytokeratin 5/6.

Total body computerized tomography performed after surgical treatment revealed the presence of right cervical, supraclavicular, mediastinal, and paratracheal lymphadenopathy. There were no alterations like metastatic lesions in lung, liver, spleen, and/or other organs.

One month after the total thyroidectomy, the patient started adjuvant chemotherapy and she was treated for 6 cycles with Doxorubicin, Dacarbazine, Ifosfamide, and Mesna (MAID).

On June 2012, December 2012 and June 2013, after adjuvant chemotherapy, a total body TAC has been performed and there were no alterations like metastatic lesions in lymph nodes, lung, liver, spleen, and/or other organs. The patient is still alive without both local systemic recurrence of the disease after 22 months from surgery.
3. Discussion

In this paper we describe the first case of thyroid angiosarcoma identified in Southern Italy (Calabria), in nonalpine area. The incidence of this uncommon tumor is highest in European Alpineregions [1, 12–14], whereas few cases of thyroid angiosarcoma have been described in nonalpine areas. In the English literature have been reported only 22 cases of non-alpine thyroid angiosarcoma, including the case described in this paper [15–19]. In total, 11 of 22 patients (50%) with non-Alpine thyroid angiosarcoma were living in Italy. The explanation of this phenomenon is unknown. Thyroid angiosarcoma is more frequent in the female respect the male (female male ratio, 9:3) [16] and the age at diagnosis ranges from 50 to 88 years [16]. Even in our case the age at diagnosis was 49 years old and the patient showed both ultrasonographic and biochemical features of the Hashimoto thyroiditis. As previously reported [20], also our case was associated with long standing nodular goiter and regressive changes including intranodular hemorrhage. As suggested, these alterations could provide the anatomic substrate for the development of the vascular tumors [16]. Indeed, Sapino et al. [21] reported that prominent endothelial hyperplasia is present in goiter nodules that underwent intranodular hemorrhage, and reorganization phenomena of the Masson's hemangiomatype and these events could represent a predisposing condition for subsequent neoplastic transformation [21]. However, there are considerable controversy about the true existence of thyroid angiosarcomas. Although it is histologically defined as cleft-like anastomosing spaces lined by large, atypical cells of endothelial lineage [7], some authors believe that most of the reported cases are anaplastic or undifferentiated carcinomas with angiomatoid features [3, 4]. Many authors believe that thyroid angiosarcoma is a variant of sarcomatoid carcinoma, in view of their nearly constant cytokeratin positivity in the neoplastic elements. On the other hand, other authors believe that true thyroid angiosarcoma of the thyroid does exist, though it is rarely observed [20]. Advances in immunohistochemistry have not helped to clarify this dispute.

Surgical resection to obtain the local control of thyroid angiosarcoma remains the still point of primary treatment. However, thyroid angiosarcoma is a very aggressive tumor. Indeed, it can rapidly spread to the cervical lymph nodes, lungs, and brain or can metastasize to the duodenum, small bowel and large bowel and induce severe bleeding [1, 4–6]. Metastatic disease is associated with poor prognosis and limits the mean survival time to a few months after diagnosis and surgical treatment. For this reason, the use of adjuvant chemotherapy and/or radiotherapy to obtain both the systemic control and local control of the disease has been introduced. Most patients develop postoperative early systemic metastasis, and it has been hypothesized that undetected micrometastases could be present at the time of the diagnosis [3]. Goh et al. [17], in a brief review on nonalpine
epithelioid angiosarcoma, reported that the majority of cases with documented extrathyroidal extension at the time of the diagnosis had a uniformly poor prognosis with death occurring within 9 months. On the other hand, a good prognosis seems to be related to the absence of extraglandular extension at the time of the diagnosis as reported by Maiorana et al. [15]. In these cases, the patients are still alive with no evidence or residual disease also after 66 months after thyroidectomy (range of 21–66 months) [2, 15]. Although our patient showed an extraglandular tumour spread with involvement of cervical, supraclavicular paratracheal, and mediastinal lymph nodes at time of the surgical treatment, the adjuvant chemotherapy with Doxorubicin, Dacarbazine, Ifosfamide, and Mesna (MAID) was able to induce a reduction of metastatic disease. Indeed, the patient is still alive without both local and systemic recurrence of the disease after 22 months from surgery.

In conclusion, thyroid angiosarcoma is an uncommon thyroid carcinoma and it is also a very aggressive tumor with a poor prognosis. Surgical resection remains the still point of primary treatment. However, our case showed that MAID combination chemotherapy may have an important role in the treatment of thyroid angiosarcoma in nonolder patients.

Consent
The authors confirm that written informed consent has been obtained from patient for publication of the submitted paper.

Disclosure
The study has not been presented in any form in any meeting or forum and the paper is not under consideration in any other journal. The authors declare that this research did not receive any specific grant from any funding agency in the public, commercial, or not-for-profit sector.

Conflict of Interests
The authors declare that there is no conflict of interests regarding the publication of this paper.

Authors’ Contribution
Nadia Innaro was the patient’s physician; Nadia Innaro, Elena Succurro, and Franco Arturi had full access to all of the data in the study and took responsibility for the integrity of the data and the accuracy of the data analysis; Giuseppe Tomaino, Elena Succurro, and Franco Arturi were responsible for both acquisition and literature review; Elena Succurro and Franco Arturi drafted the paper. All authors have read the paper and agreed on the content. Nadia Innaro and Elena Succurro contributed equally to this work.

Acknowledgments
The authors wish to thank Dr. V. Tucci “Pugliese Hospital” for his contribution in the histological diagnosis.

References
[1] Y. F. Chan, L. Ma, J. H. Boey, and H. Y. Yeung, “Angiosarcoma of the thyroid. An immunohistochemical and ultrastructural study of a case in a Chinese patient,” Cancer, vol. 57, no. 12, pp. 2381–2388, 1986.
[2] A. Ryška, M. Ludvíková, P. Szépe, and A. Böör, “Epithelioid haemangiosarcoma of the thyroid gland. Report of six cases from a non-Alpine region,” Histopathology, vol. 44, no. 1, pp. 40–46, 2004.
[3] T. Yilmazlar, T. Kirdak, S. Adim, E. Ozturk, and O. Yerci, “A case of hemangiosarcoma in thyroid with severe anemia due to bone marrow metastasis,” Endocrine Journal, vol. 52, no. 1, pp. 57–59, 2005.
[4] D. Bandorski, H. Arps, D. Jaspersen, and K. L. Diehl, “Severe intestinal bleeding caused by intestinal metastases of a primary angiosarcoma of the thyroid gland,” Zeitschrift fur Gastroenterologie, vol. 40, no. 9, pp. 811–814, 2002.
[5] W. Rhomberg, F.-K. Böhler, H. Eiter, H. Fritzsche, and G. Breitfellner, “Malignant hemangioendothelioma of the thyroid. New results related to pathogenesis, treatment, and prognosis,” Wiener Klinische Wochenschrift, vol. 110, no. 13-14, pp. 479–484, 1998.
[6] J. Astl, J. Dušková, Z. Limanová, C. Povýšil, and Z. Kuchynková, “Hemangiosarcoma of the thyroid gland. A case report,” Neuroendocrinology Letters, vol. 21, no. 3, pp. 213–216, 2000.
[7] N. R. Kim, Y.-H. Ko, and C. O. Sung, “A case of coexistent angiosarcoma and follicular carcinoma of the thyroid,” Journal of Korean Medical Science, vol. 18, no. 6, pp. 908–913, 2003.
[8] K. Krisch, J. H. Holzner, and R. Kokoschka, “Hemangioendothelioma of the thyroid gland—True endothelioma or anaplastic carcinoma?” Pathology Research and Practice, vol. 170, no. 1–3, pp. 230–242, 1980.
[9] P. Lampertico, “Anaplastic (sarcomatoid) carcinoma of the thyroid gland,” Seminars in Diagnostic Pathology, vol. 10, no. 2, pp. 159–168, 1993.
[10] S. E. Mills, R. G. Stallings, and M. B. Austin, “Angiomatoid carcinoma of the thyroid gland: anaplastic carcinoma with follicular and medullary features mimicking angiosarcoma,” American Journal of Clinical Pathology, vol. 86, no. 5, pp. 674–678, 1986.
[11] S. E. Mills, M. J. Gaffey, J. C. Watts et al., “Angiomatoid carcinoma and “angiosarcoma” of the thyroid gland: a spectrum of endothelial differentiation,” American Journal of Clinical Pathology, vol. 102, no. 3, pp. 322–330, 1994.
[12] F. Eckert, U. Schmid, F. Gloor, and H. C. Hedinger Ch., “Evidence of vascular differentiation in anaplastic tumours of the thyroid—an immunohistological study,” Virchows Archiv, vol. 410, no. 3, pp. 203–215, 1986.
[13] H. C. Hedinger Chr., “Geographic pathology of thyroid diseases,” Pathology Research and Practice, vol. 171, no. 3–4, pp. 285–292, 1981.
[14] M. Totsch, G. Dobler, H. Feichtinger, P. Sandbichler, D. Ladurner, and K. W. Schmid, “Malignant hemangioendothelioma of the thyroid. Its immunohistochemical discrimination from undifferentiated thyroid carcinoma,” American Journal of Surgical Pathology, vol. 14, no. 1, pp. 69–74, 1990.
[15] A. Maiorana, G. Collina, A. M. Cesinaro, R. A. Fano, and V. Eusebi, “Epithelioid angiosarcoma of the thyroid. Clinicopathological analysis of seven cases from non-Alpine areas,” Virchows Archiv, vol. 429, no. 2-3, pp. 131–137, 1996.
[16] V. Eusebi, M. L. Carcangi, R. Dina, and J. Rosai, “Keratin-positive epithelioid angiosarcoma of thyroid. A report of four
cases,” American Journal of Surgical Pathology, vol. 14, no. 8, pp. 737–747, 1990.

[17] S. G. N. Goh, K. L. Chuah, H. K. C. Goh, and Y. Y. C. Chen, “Two cases of epithelioid angiosarcoma involving the thyroid and a brief review of non-Alpine epithelioid angiosarcoma of the thyroid,” Archives of Pathology & Laboratory Medicine, vol. 127, no. 2, pp. E70–E73, 2003.

[18] P. Petronella, M. Scorzelli, R. Luise et al., “Primary thyroid angiosarcoma: an unusual localization,” World Journal of Surgical Oncology, vol. 10, article 73, 2012.

[19] P. Gouveia, C. Silva, F. Magalhães et al., “Non-Alpine thyroid angiosarcoma,” International Journal of Surgery Case Reports, vol. 4, no. 5, pp. 524–527, 2013.

[20] M. Papotti, M. Volante, F. Negro, V. Eusebi, and G. Bussolati, “Thyroglobulin mRNA expression helps to distinguish anaplastic carcinoma from angiosarcoma of the thyroid,” Virchows Archiv, vol. 437, no. 6, pp. 635–642, 2000.

[21] A. Sapino, M. Papotti, L. Macri, M. A. Satolli, and G. Bussolati, “Intranodular reactive endothelial hyperplasia in adenomatous goitre,” Histopathology, vol. 26, no. 5, pp. 457–462, 1995.